From: Patient’s perspective of sustained remission in rheumatoid arthritis
Outcome, (N° of patients who achieved norm in DAS28-SR/B-SR patients) | Months of follow-up to outcome normalization in 78 DAS28-SR patientsa | Months of follow-up to outcome normalization in 63 B-SR patientsa |
---|---|---|
ESR-N, (77/61) | 1.5 ± 3 | 2 ± 4 |
CRP-N, (73/63) | 2.9 ± 4.4 | 2.4 ± 3.7 |
HAQ-N, (75/63) | 6 ± 5.1 | 4.8 ± 4.2 |
PVAS-N, (77/63) | 6.1 ± 4.6 | 4.8 ± 3.2 |
OVAS-N, (76/63) | 6.1 ± 4.7 | 4.9 ± 3.4 |
SF-36-N, mental component, (67/54) | 6.2 ± 4.7 | 5.6 ± 4.3 |
SF-36-N, physical component, (60/48) | 7 ± 5.5 | 5 ± 3.3 |
Tender joint count ≤1(0–68 joints), (76/63) | 7.6 ± 4.9 | 7 ± 4.5 |
Swollen joint count ≤1 (0–66 joints), (72/63) | 7.7 ± 4.8 | 7.7 ± 4.9 |
Physician overall disease ≤10 (0-100 mm), (77/63) | 8.6 ± 4.4 | 8.1 ± 4.6 |
Absence of substantial fatigue, (34/24) | 8.7 ± 5.4 | 6.4 ± 4.3 |